Source comparison
TB-500 Cardiac Repair: Comparison Table
This table compares TB-500 to other regenerative peptide candidates evaluated in cardiac repair research. | Peptide | Primary Mechanism | Clinical Trial Phase | LVEF Improvement (vs Placebo) | Fibrosis Reduction | Administration Route | Bottom Line ||—|—|—|—|—
This comparison does not assign a generated winner or score.
- This table compares TB-500 to other regenerative peptide candidates evaluated in cardiac repair research.
- | Peptide | Primary Mechanism | Clinical Trial Phase | LVEF Improvement (vs Placebo) | Fibrosis Reduction | Administration Route | Bottom Line ||—|—|—|—|—|—|| TB-500 (Thymosin β4) | Actin regulation, angiogenesis, progenitor activation | Phase II completed | +12–19% at 6 months | 37% reduction (preclinical) | IV bolus + SC weekly | Strongest evidence for post-MI border zone preservation; limited effect on established scar || BPC-157 | Nitric oxide upregulation, VEGF pathway | Preclinical only | Not assessed in humans | Not quantified | SC injection | Promising angiogenic activity but no human cardiac data || GHK-Cu (Copper peptide) | Collagen remodeling, anti-inflammatory | Phase I | +4–6% (non-significant) | Minimal | Topical/SC | Mechanism does not translate to deep myocardial tissue || Cartalax Peptide | Telomere protection, cellular senescence | Preclinical | Not assessed | Not quantified | SC injection | Indirect cardioprotective effects via systemic aging pathways; not MI-specifi